 |
|
|
 |
|
|
|
| |
|
What is Merial's business? |
|
| |
|
What is Merial’s vision? |
|
| |
 |
When was Merial founded? |
|
| |
|
How many people are employed by Merial? |
|
| |
|
What are Merial’s total sales? |
|
| |
|
Who leads Merial's senior management team? |
|
| |
|
Who are Merial’s shareholders? |
|
| |
|
Does Merial have a stock market listing? |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| |
Q. |
What is Merial's business? |
|
| |
A. |
Merial is an innovation-driven leader in the provision of products and solutions that enhance the health, well-being and performance of animals. |
| |
| |
Q. |
What is Merial’s vision? |
|
| |
A. |
Merial will be the recognized benchmark in providing value to our customers, employees and shareholders. |
| |
| |
Q. |
When was Merial founded? |
|
| |
A. |
Merial was founded in August 1997 through the merger of the animal health businesses of Merck and Co., Inc. and Rhone Merieux, a predecessor to sanofi-aventis. |
| |
| |
Q. |
How many people are employed by Merial? |
|
| |
A. |
Merial employs more than 5,700 people worldwide. |
| |
| |
Q. |
What are Merial’s total sales? |
|
| |
A. |
Total 2008 sales were over $2.6 billion. |
| |
| |
Q. |
Who leads Merial's senior management team? |
|
| |
A. |
Jose Barella is the Executive Chairman. |
| |
| |
Q. |
Who are Merial’s shareholders? |
|
| |
A. |
Merial is a Animal Health subsidiary of sanofi-aventis. |
| |
| |
Q. |
Does Merial have a stock market listing? |
|
| |
A. |
No. Merial is a Animal Health subsidiary of sanofi-aventis, which is listed on the Paris Stock Exchange. |
| |
| |
Q. |
What are Merial’s leading products? |
|
| |
A. |
Merial has leading products in a wide range of veterinary specialties, notably in the fields of anaesthetic, antiparasitic, antimicrobial, gastrointestinal, respiratory and cardiovascular medicines, and produces a range of vaccines to protect a wide variety of species against disease.
Merial's best known products are probably their best selling antiparasitics. IVOMEC® (ivermectin) -- which was first launched in 1981 for treatment and protection against parasites in large animals such as cattle, sheep and swine ---- is the world’s single most successful animal health product. FRONTLINE® (fipronil) -- which was first launched in 1984 -- has established a parallel position in dogs and cats and is now the world’s best selling flea and tick treatment for those species.
Merial’s pharmaceuticals are supported by a wide range of vaccines. We are specialists in the area of avian protection, offering a range of vaccines to protect birds, particularly poultry, against a range of common and life-threatening diseases such as Newcastle Disease, Marek's Disease and Avian Flu. Merial is also well-known for its antirabies vaccines for use in domestic and wild animals and for its foot and mouth disease vaccine, which was pioneered by the Institut Mérieux the French forerunner of the present company.
Other Merial best sellers include HEARTGARD® (ivermectin), EQVALAN® (ivermectin), GASTROGARD® (omeprazole), ULCERGARD® (omeprazole) and PUREVAX®.
|
| |
| |
Q. |
In which countries does Merial operate? |
|
| |
A. |
Merial’s main markets are the United States, France, Brazil, the United Kingdom, Italy, Canada, Benelux, Germany, Australia and Argentina. |
| |
| |
Q. |
What is Merial’s main customer base? |
|
| |
A. |
Merial’s customers include veterinarians, pet owners, farmers and food animal producers worlwide. |
| |
| |
Q. |
What is Merial’s R & D focus? |
|
| |
A. |
Merial is advancing in four main areas: parasiticides, antibiotics, pain control, and products for treating chronic conditions in companion animals. We are also exploring and developing new ranges of vaccines which employ both conventional and novel technologies with the objective of offering enhanced protection to a wide range of animal species. For further information on our research and development, please visit the research and development page. |
| |
|
|
|
